Dawn of hope: Global cooperation in COVID-19 vaccine development

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BEIJING, Sept. 4, 2020 /PRNewswire/ — A news report by China.org.cn on international cooperation for vaccine R&D and China’s recent efforts:

On Aug. 20 and 21, China National Biotec Group, a subsidiary of China National Pharmaceutical Group, signed cooperation agreements with Peru, Morocco and Argentina to conduct Phase III clinical trials of an inactivated COVID-19 vaccine.

The results of its Phase I and II clinical trials in June showed no severe adverse reactions and all those administered with the vaccine produced high titers of antibodies. On June 23, the vaccine candidate started its Phase III clinical trial in the United Arab Emirates. It is the world’s first Phase III trial of an inactivated vaccine, and also the first overseas clinical trial of a Chinese-developed vaccine.

In contrast with recombinant COVID-19 vaccines, inactivated vaccines use killed virus to help the human body develop an immune response.

China hopes to develop a safe and effective vaccine against COVID-19 as fast as possible. The country will make its vaccine a global public good, and do its utmost to improve affordability and availability of the vaccine. Phase III clinical trials can only be clearly assessed by administering the vaccine in risky areas. The outbreak in China is now under control, which provides the country with no suitable condition to conduct a Phase III clinical trial. Therefore, international cooperation is essential to such clinical trials. A large amount of data from multiple regions will also greatly accelerate development of the vaccine.

Researchers around the world are racing to develop a COVID-19 vaccine, with more than 170 candidates now being tracked by the WHO. Potential vaccines developed by the U.K., the U.S. and Australia have all entered Phase III clinical trials. This is definitely good news for all.

Apart from vaccine development, Chinese enterprises are also actively working with their international counterparts to put in place the relevant industrial chains. A Chinese pharma company has signed a letter of intent with its German partner to help the latter complete clinical trials of potential COVID-19 vaccines in China and obtain marketing approval.

In order to guarantee equal access to COVID-19 vaccines for every country, the WHO launched the COVID-19 Vaccine Global Access Facility (COVAX) initiative. What China is doing is in essence the same with COVAX.

The COVID-19 situation varies from country to country, but an effective vaccine will offer protection for all. No country can develop a successful vaccine without international cooperation. In this global battle against the coronavirus, the dawn of hope has come.

China Mosaic
http://www.china.org.cn/video/node_7230027.htm

Dawn of hope: Global cooperation in COVID-19 vaccine development
http://www.china.org.cn/video/2020-09/03/content_76667267.htm

View original content to download multimedia:http://www.prnewswire.com/news-releases/dawn-of-hope-global-cooperation-in-covid-19-vaccine-development-301124350.html

SOURCE China.org.cn

Staff

Recent Posts

FinThrive Introduces Agentic AI at HFMA 2025 to Help Customers Transform Healthcare Revenue Cycle Management Performance

Company to also highlight advancements in denials and underpayments management and speak to the measurable…

11 hours ago

FinThrive Debuts Denials and Underpayments Analyzer, a Unified Solution for Denials and Underpayments, at HFMA 2025

Next generation analyzer helps hospitals protect revenue before it's lost by delivering timely end-to-end visibility…

11 hours ago

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction…

14 hours ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project as Federal Support for Blockchain Grows

Dr. Anosh Ahmed repurposes West Side warehouse into blockchain innovation center, targeting 250+ jobs and…

14 hours ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project Amid National Pro-Crypto Policy Shift

Dr. Anosh Ahmed converts vacant West Side warehouse into blockchain innovation hub, creating 250+ jobs…

14 hours ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits…

14 hours ago